Search:

 

Search for text in:

separate each search
term with a space
Multiple terms:

Additional Search Filters:

clear all | select all

Session type:

Availability:

clear all | select all

Conference years:

clear all | select all

Group type:

clear all | select all

Participation Type:

clear all | select all

Has CME:

clear all | select all

Access:

clear all | select all

Categories:

 
 
Display by: Sort by:
<< first | < prev page: of 16 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 13 14 15 16 sessions: 1 to 25 of 395
Workshop: New Investigators and Trainees (Part 1)
Transmission/Founder Viruses and Their Phenotypic Properties
Beatrice Hahn
Univ of Pennsylvania, Philadelphia, US
Research on Viral Reservoirs, Persistence, and Cure
Mario Stevenson
Univ of Miami Miller Sch of Med, FL, US
Recent Advances in HIV and SIV Pathogenesis
Guido Silvestri
Emory Univ Sch of Med and Yerkes Natl Primate Res Ctr, Atlanta, GA, US
from 20th Conference on Retroviruses on March 3, 2013 9:00 AM-10:45 AM
Workshop: New Investigators and Trainees (Part 2)
HIV Prevention Research: What's Next?
Susan Buchbinder
San Francisco Dept of Publ Hlth, CA, US
Hepatitis C Virus Research and Treatment
Robert Schooley
Univ of California, San Diego, US
from 20th Conference on Retroviruses on March 3, 2013 11:15 AM-12:30 PM
Workshop: New Investigators and Trainees Martin Delaney Lecture
The Challenge of Marginalization in the Fight against HIV, and the Resiliency of Individuals and Communities
Paul Semugoma
African Men for Sexual Hlth and Rights, ANOVA Hlth, South Africa
from 20th Conference on Retroviruses on March 3, 2013 12:45 PM-1:30 PM
Workshop: Frontiers in Laboratory Science
In Vivo Imaging of Viral and Cellular Dynamics in HIV Infection
Thorsten Mempel
Ctr for Immunology and Inflammatory Diseases, Massachusetts Gen Hosp, Boston, US and Harvard Med Sch, Boston, MA, US
Systems Vaccinology: Its Promise and Challenge for HIV Vaccine Development
Helder Nakaya
Emory Univ Sch of Med, Atlanta, GA, US
Crowd-sourcing, Social Networks, and Twitter Research in Infectious Diseases
Marcel Salathe
Ctr for Infectious Disease Dynamics, Pennsylvania State Univ, University Park, US
Using Viral Meta-genomics to Identify “Novel” Human and Animal Viruses
Eric Delwart
Blood Systems Res Inst and Univ of California, San Francisco, US
from 20th Conference on Retroviruses on March 3, 2013 2:30 PM-4:30 PM
Workshop: Clinical Trials Design
Adaptive Methods: What You Really Need to Know
Michael Proschan
Biostatistics Res Branch, NIAID, NIH, Bethesda, MD, US
Alternatives to Randomized Controlled Trials: When and How to Use
Caroline Sabin
Univ Coll London, UK
The Symbiotic Relationship between Trials and Mathematical Models
Timothy Hallett
Imperial Coll London, UK
from 20th Conference on Retroviruses on March 3, 2013 2:30 PM-4:30 PM
Opening Session
Greetings from the Program Committee
Kevin De Cock
CDC Kenya, Nairobi
Remarks from the Director of the US Centers for Disease Control and Prevention
Thomas Frieden
CDC, Atlanta, GA, US
18th Bernard Fields Lecture: ARV Drug Discovery: HIV-1 Integrase Inhibitors and Beyond
Daria Hazuda
Merck Res Labs, West Point, PA, US
7th N'Galy-Mann Lecture: MTCT: From Epidemic to Elimination
Lynne Mofenson
Natl Inst of Child Hlth and Human Devt, NIH, Rockville, MD, US
from 20th Conference on Retroviruses on March 3, 2013 5:00 PM-7:00 PM
Plenary
HIV-1 Eradication Strategies: Design, Assessment, and Clinical Consequences
Robert Siliciano
Johns Hopkins Univ Sch of Med, Baltimore, MD, US
from 20th Conference on Retroviruses on March 4, 2013 8:30 AM-9:00 AM
Plenary
Reality Check: Is the End of AIDS in Sight?
Francois Dabis
Bordeaux Sch of Publ Hlth and INSERM U897, Univ Bordeaux, Segalen, France
from 20th Conference on Retroviruses on March 4, 2013 9:00 AM-9:30 AM
Oral Abstract: Neurocognitive Disorders: New Developments and Therapies
Very Early Viral Infection of the Central Nervous System without Evidence of Compartmentalization during Acute HIV-1 Infection (RV254)
Serena Spudich
Yale Univ, New Haven, CT, US
Neuropsychological Performance in Acute HIV: Determinants of Baseline Performance and Effects of Immediate ART
Idil Kore
Yale Univ Sch of Med, New Haven, CT, US
A Randomized, Controlled Trial of a Central Nervous System-targeted ART Strategy for HIV-associated Neurocognitive Disorders
Ronald Ellis
Univ of California, San Diego, US
Regional Brain Atrophy Is Associated with Mitochondrial Dysfunction and Elevated Mitochondrial Oxidative Stress in HIV+ Individuals
Cecilia Shikuma
Univ of Hawaii, Honolulu, US
VLA-4 Treatment Blocks Virus Traffic to the Gut and Brain Early, and Stabilizes CNS Injury Late in Infection
Jennifer Campbell
Boston Coll, Chestnut Hill, MA, US
Central Nervous System Compartmentalization of HIV-1 Subtype C Variants Early and Late in Infection in Young Children
Christa Buckheit Sturdevant
Univ of North Carolina at Chapel Hill, US
from 20th Conference on Retroviruses on March 4, 2013 10:00 AM-11:30 AM
Oral Abstract: HIV Prevention: ARV, Counseling, Contraception, and Condoms
Long-acting Parenteral Formulation of GSK1265744 Protects Macaques against Repeated Intrarectal Challenges with SHIV
Chasity Andrews
Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New York, NY, US
A Tenofovir Disoproxil Fumarate Intravaginal Ring Completely Protects against Repeated SHIV Vaginal Challenge in Nonhuman Primates
James Smith
CDC, Atlanta, GA, US
Pre-exposure Prophylaxis for HIV in Women: Daily Oral Tenofovir, Oral Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 003)
Jeanne Marrazzo
Univ of Washington, Seattle, US
No Excess In HIV Incidence after Stopping Oral Emtricitabine/Tenofovir Pre-exposure Prophylaxis: The iPrEx Trial
Robert Grant
Gladstone Inst, San Francisco, CA, US and Univ of California, San Francisco, US
Hormonal Contraception and Risk of HIV: An analysis of data from the Microbicides Development Programme Trial
Angela Crook
MRC Clin Trials Unit, London, UK
Is Depot Medroxyprogesterone Acetate Likely to Increase Infectivity in HIV-1+ Women Receiving ART?
Summer Day
Univ of Washington, Seattle, US
Community-level Reductions in Estimated HIV Incidence: HIV Prevention Trials Network 043, Project Accept
Thomas Coates
Univ of California, Los Angeles, US
Which HIV Testing and Counseling Model Works Best in African Outpatient Departments? Results from the Strengthening HIV Test Access and Treatment Uptake Study
AD McNaghten
Emory Univ, Atlanta, GA, US
Condom Efficacy by Consistency of Use Among MSM: US
Dawn Smith
CDC, Atlanta, GA, US
from 20th Conference on Retroviruses on March 4, 2013 10:00 AM-12:15 PM
Oral Abstract: Advances in Hepatitis Therapy
Protective Effect of Hepatitis B Virus–active cART against Primary Hepatitis B Virus Infection
Kees Brinkman
Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
Increased Plasma and Intracellular Ribavirin Concentrations Associated with Telaprevir Use
Kyle Hammond
Univ of Colorado Denver, Aurora, US
Pharmacokinetic Interactions of Darunavir/ritonavir, Efavirenz, and Tenofovir with the Hepatitis C Virus Protease Inhibitor Faldaprevir in Healthy Volunteers
Jens Kort
Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, US
High Early Virological Response with Telaprevir-Pegylated-Interferon-Ribavirin in Treatment-experienced Hepatitis C Virus Genotype 1/HIV Co-infected Patients: ANRS HC26 TelapreVIH Study
Laurent Cotte
INSERM U1052, Hospices Civils de Lyon, France
ANRS-HC27 BocepreVIH Interim Analysis: High Early Virologic Response with Boceprevir + Pegylated Interferon + Ribivirin in Hepatitis C Virus/HIV Co-infected Patients with Previous Failure to Pegylated Interferon + Ribivirin
Isabelle Poizot-Martin
Hosp Ste Marguerite, Marseille, France
12 Weeks of ABT-450/Ritonavir, Non-nucleoside Inhibitor and Ribavirin Achieved SVR24 in >90% of Treatment-naïve Hepatitis C Virus GT1 Patients and 47% of Prior Non-responders
Eric Lawitz
Alamo Med Res, San Antonio, TX, US
Risk of Virologic Relapse in Hepatitis C Virus GT1-infected Subjects after 8, 12, and 24 Weeks of ABT-450/r+ABT-267+ABT-333+Ribavirin: Identifying Optimal Treatment Duration
Martin King
AbbVie, North Chicago, IL, US
STARTVerso 4: High Rates of Early Virologic Response in Hepatitis C Virus Genotype 1/HIV Co-infected Patients Treated with Faldaprevir + Pegylated Interferon and Ribavirin
Douglas Dieterich
Mt Sinai Sch of Med, New York, NY, US
ELECTRON: 100% Suppression of Viral Load through 4 Weeks Post-treatment for Sofosbuvir + Ledipasvir (GS-5885) + Ribavirin for 12 Weeks in Treatment-naïve and -experienced Hepatitis C Virus GT1 Patients
Edward Gane
Auckland Clin Studies, New Zealand
from 20th Conference on Retroviruses on March 4, 2013 10:00 AM-12:15 PM
Oral Abstract: Is There Hope for HIV Eradication?
Increase in 2-LTR Circles After Raltegravir Intensification in HAART-suppressed Patients with High CD4+ T Cell Counts: A Randomized, Controlled Trial
Hiroyu Hatano
Univ of California, San Francisco, US
Characterization of Non-induced HIV-1 Proviruses Dampens the Hope for HIV-1 Eradication
Ya-Chi Ho
Johns Hopkins Univ Sch of Med, Baltimore, MD, US
T Memory Stem Cells Are a Long-term Reservoir for HIV-1
Maria Buzon
Ragon Inst of MGH, MIT and Harvard, Boston, MA, US
High Levels of CD2 Expression Identify HIV-1 Latently Infected Resting Memory CD4+ T Cells in Virally Suppressed Subjects
Fabio Romerio
Inst of Human Virology, Baltimore, MD, US
Study of Transitional Memory CD4+ T Cells and γδ T Cells as Latent Reservoirs for Replication Competent HIV-1
Natalia Soriano-Sarabia
Univ of North Carolina at Chapel Hill, US
Early ART Intervention Restricts the Seeding of the HIV Reservoir in Long-lived Central Memory CD4 T Cells
Jintanat Ananworanich
SEARCH, Bangkok, Thailand; The Thai Red Cross AIDS Res Ctr, Bangkok; HIVNAT, Bangkok, Thailand; and Faculty of Med, Chulalongkorn Univ, Bangkok, Thailand
Functional HIV Cure after Very Early ART of an Infected Infant
Deborah Persaud
Johns Hopkins Univ Sch of Med, Baltimore, MD, US
Novel Approaches for the Assessment of the in vivo Residual Virus Pool and Viral Eradication Strategies in SIV+ Rhesus Macaques
Gregory Del Prete
AIDS and Cancer Virus Prgm, SAIC-Frederick, Inc, Frederick Natl Lab for Cancer Res, MD, US
The Safety and Effect of Multiple Doses of Vorinostat on HIV Transcription in HIV+ Patients Receiving cART
Sharon Lewin
Alfred Hosp, Melbourne, Australia; Monash Univ, Melbourne, Australia; and Burnet Inst, Melbourne, Australia
from 20th Conference on Retroviruses on March 4, 2013 10:00 AM-12:15 PM
Themed Discussion: Simian Viral Reservoirs
Discovery of Novel and Highly Divergent SIV in Three Wild Monkey Species in Kibale National Park, Uganda
William Switzer
CDC, Atlanta, GA, US
Full-length Genome Analyses of Two Highly Divergent SIVmus Strains Isolated in Mustached Monkeys (C. cephus) Hunted for Bushmeat in Gabon
Florian Liegeois
UMI 233, Inst de Recherche pour le Devt and Univ of Montpellier, France and Ctr Intl de Recherches Med de Franceville, Gabon
Gorillas in Southwest Cameroon Are the Reservoir of HIV-1 Group P Ancestors
Mirela D'arc
UMI 233, IRD and Univ of Montpellier 1, France and Univ Federal do Rio de Janeiro, Brazil
Non-Invasive Follow-up of SIVcpzPtt Infection in Wild-living Chimpanzees in Northeast Gabon
Vanina Boue
UMI 233, Inst de Recherche pour le Devt and Univ of Montpellier, France and Ctr Intl de Recherches Med de Franceville, Gabon
Expanded Screening for Simian Foamy Virus in New World Primates Identifies 2 Novel Simian Foamy Virus in Tamarin and Uakari Monkeys from Brazil
Claudia Muniz
Univ Federal do Rio de Janeiro, Brazil
Co-infection of Wild African Primates with SIV and Simian Hemorrhagic Fever Viruses
Tony Goldberg
Univ of Wisconsin-Madison, US; Wisconsin Natl Primate Res Ctr, Madison, US; and Kibale EcoHlth Project, Makerere Univ Bio Field Station, Kanyawara, Uganda
from 20th Conference on Retroviruses on March 4, 2013 1:30 PM-2:30 PM
Themed Discussion: Tenofovir in Children
Tenofovir Disoproxil Fumarate Use in Children and Youth
Peter Havens
Med Coll of Wisconsin, Children's Hosp of Wisconsin, Children's Res Inst, Milwaukee, US
48-Week Safety of Tenofovir when Administered According to Weight-band Dosing in HIV+ Children >15 Kg as Part of a Once-daily HAART Regimen
Virat Sirisanthana
Chiang Mai Univ, Thailand
Pharmacokinetics of Tenofovir in Thai Adolescents Using Ritonavir-boosted Protease Inhibitor-based Regimens
Jintanat Ananworanich
SEARCH, Bangkok, Thailand; The Thai Red Cross AIDS Res Ctr, Bangkok; HIVNAT, Bangkok, Thailand; and Faculty of Med, Chulalongkorn Univ, Bangkok, Thailand
Panel Discussion
from 20th Conference on Retroviruses on March 4, 2013 1:30 PM-2:30 PM
Themed Discussion: New Approaches to ARV Drug Delivery
Challenges and Opportunities for the Development of Long-­acting ARVs
Marta Boffito
Chelsea and Westminster Hosp, London, UK
Improved Biodistribution, Pharmacokinetics, and ARV Responses for Folate-targeted Nanoformulated ART
Pavan Puligujja
Univ of Nebraska Med Ctr, Omaha, US
Development of Small Magnetite ARV Nanoparticles for Targeted Drug Delivery to Viral Reservoirs
Dongwei Guo
Univ of Nebraska Med Ctr, Omaha, US
Enhanced Pharmacological Properties of Efavirenz Formulated as Solid Drug Nanoparticles
Neill Liptrott
Univ of Liverpool, UK
Concluding Comments: The Regulatory Pathway for Development of Long-­acting ARVs
Kimberly Struble
FDA, Silver Spring, MD, US
from 20th Conference on Retroviruses on March 4, 2013 1:30 PM-2:30 PM
Themed Discussion: Implementation and Cost-effectiveness of Male Circumcision
Shang Ring vs Forceps-guided Adult Male Circumcision, a Randomized Controlled Effectiveness Study: Western Uganda
Samuel Kanyago
Mbarara Univ of Sci and Tech, Uganda and Good Shepherd Hosp, Siteki, Swaziland
Factors Associated with Voluntary Medical Male Circumcision Adverse Events: Nyanza Province, Kenya
Kipruto Chesang
CDC, Ctr for Global Hlth, Nairobi, Kenya
Male Circumcision Coverage by Risk Profiles: Rakai, Uganda
Xiangrong Kong
Johns Hopkins Univ, Baltimore, MD, US
Costs and Effectiveness of Male Circumcision Scale-up for the Prevention of HIV and Other Sexually Transmitted Infections: Sub-Saharan Africa
Seema Kacker
Johns Hopkins Univ Sch of Med, Baltimore, MD, US
Uptake of Neonatal Male Circumcision as part of HIV Prevention Efforts in Botswana: Maternal Motivators and Barriers
Rebeca Plank
Brigham and Women's Hosp; Harvard Sch of Publ Hlth; and Botswana-Harvard Partnership
from 20th Conference on Retroviruses on March 4, 2013 1:30 PM-2:30 PM
Themed Discussion: What Is Latency and What Can We Do about It?
Only a Small Fraction of HIV-1 Proviruses in Resting CD4+ T Cells Can Be Induced to Produce Virions ex vivo with Anti-CD3/CD28 or Vorinostat
Anthony Cillo
Univ of Pittsburgh, PA, US
A Comparison of Methods Used to Measure Rectal HIV Levels Suggests that HIV DNA Resides in Cells Other than CD4+ T Cells, Including CD45+CD13+ Cells
Steven Yukl
San Francisco VAMC, CA, US and Univ of California, San Francisco, US
Integrated HIV DNA and Associated Histiocyte Marker mRNA in Autopsy Samples of Non-lymphoid Tissue Including the Central Nervous System
Benjamin Gelman
Univ of Texas Med Branch, Galveston, US
HIV Preferentially Infects Hematopoietic Progenitor Cells with High CD4 and Can Be Found in CD133+ Hematopoietic Progenitor Cells in a Subset of Optimally Treated People with Long-term Viral Suppression
Lucy McNamara
Univ of Michigan, Ann Arbor, US
Differences in Integration Site Distributions for Latent and Expressed HIV-1 Proviruses
Scott Sherrill-Mix
Univ of Pennsylvania, Philadelphia, US
Histone Deacetylase Inhibitor Romidepsin Induces HIV in CD4+ T Cells from ART-suppressed Subjects at Concentrations Achieved by Clinical Dosing
George Wei
Gilead Sci Inc, Foster City, CA, US
from 20th Conference on Retroviruses on March 4, 2013 1:30 PM-2:30 PM
Themed Discussion: Statin Use and HIV: How Sweet Is It?
Statin Therapy and Mortality in HIV+ Individuals: A Danish Nationwide Population-based Cohort Study
Line Rasmussen
Odense Univ Hosp, Denmark
Impact of Statin Exposure on Mortality and Non-AIDS Complications in HIV Patients on HAART
Henning Drechsler
VA North Texas Hlth Care System, Dallas, US; and Univ of Texas Southwestern Med Ctr, Dallas, US
Association between Statin Use and Type-2 Diabetes Mellitus Occurrence among HIV-1+ Patients Receiving ART
Vincenzo Spagnuolo
San Raffaele Sci Inst, Milan, Italy
Statin Use Is Associated with Incident Diabetes Mellitus among Patients in the HIV Outpatient Study
Kenneth Lichtenstein
Natl Jewish Hlth, Denver, CO, US
from 20th Conference on Retroviruses on March 4, 2013 1:30 PM-2:30 PM
Symposium: Is Something Bugging You?
The Human Microbiome in Health and Immunodeficient States
Frederic Bushman
Univ of Pennsylvania Perleman Sch of Med, Philadelphia, US
HIV and SIV Pathogenesis at the Interface of Gut Mucosal Immune Defense and Microbiota
Satya Dandekar
Univ of California, Davis, US
Treating Microbial Translocation in Progressive HIV/SIV Infections
Jason Brenchley
Prgm in Barrier Immunity and Repair, NIAID, NIH, Bethesda, MD, US
The Enteric Virome in AIDS
Scott Handley
Washington Univ Sch of Med, St Louis, MO, US
from 20th Conference on Retroviruses on March 4, 2013 4:00 PM-6:00 PM
Symposium: Preventing HIV/AIDS in the US: Can We Do Better?
Drivers of the HIV Epidemic in the Southern US
Adaora Adimora
Univ of North Carolina at Chapel Hill, US
What Do Sexual Networks Tell Us about How to Block Transmission?
Steven Goodreau
Univ of Washington, Seattle, US
How Should We Spend Our Prevention Dollars?
Carlos del Rio
Emory Univ Ctr for AIDS Res, Atlanta, GA, US
Addressing the Cascade of Care
Alan Greenberg
George Washington Univ and District of Columbia Devt Ctr for AIDS Res, US
Panel Discussion
Panel Discussion
from 20th Conference on Retroviruses on March 4, 2013 4:00 PM-6:00 PM
Oral Abstract: Cardiovascular Disease and Other Non-AIDS Events: Epidemiology and Pathogenesis
HIV+ Adults Are at Greater Risk for Myocardial Infarction, Non-AIDS Cancer, and End-stage Renal Disease, but Events Occur at Similar Ages Compared to HIV– Adults
Keri Althoff
VAMC and George Washington Univ Med Ctr, Washington, DC, US
Combined Effect of Interleukin-6 and D-dimer on the Risk of Serious Non-AIDS Conditions: Data from 3 Prospective Cohorts
Birgit Grund
Univ of Minnesota, Minneapolis, US
Increased Risk of Cardiovascular Disease with Age in Men: A Comparison of D:A:D with HIV– Cardiovascular Disease Risk Equations
Kathy Petoumenos
The Kirby Inst, Univ of New South Wales, Sydney, Australia
Age and Noncalcified Coronary Plaque in the Multicenter AIDS Cohort Study
Wendy Post
Johns Hopkins Univ Sch of Med, Baltimore, MD, US and Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US
Increased Coronary Atherosclerotic Plaque Vulnerability Features on Computed Tomography Angiography among HIV+ Subjects vs Matched HIV– Controls
Steven Grinspoon
Massachusetts Gen Hosp, Boston, US
Elevated Numbers of CD163+ Macrophages in Hearts of SIV+ Rhesus Macaques with Cardiac Disease Are Decreased using PA300
Joshua Walker
Boston Coll, Chestnut Hill, MA, US
Comparison of Aspirin Use and Incident Myocardial Infarction Rates in HIV+ and HIV– Patients in a Large US Healthcare System
Sujit Suchindran
Massachusetts Gen Hosp, Boston, US
Monocyte Activation, but Not T Cell Activation, Predicts Progression of Coronary Artery Calcium in a Contemporary HIV Cohort
Jason Baker
Hennepin County Med Ctr, Minneapolis, MN, US and Univ of Minnesota, Minneapolis, US
from 20th Conference on Retroviruses on March 4, 2013 4:00 PM-6:00 PM
Symposium: New Frontiers in Hepatitis C Virus Treatment
The Test and Treat Era of Hepatitis C: Expanding the Individual and Public Health Benefits of Hepatitis C Virus Treatment
John Ward
CDC, Atlanta, GA, US
Pathogenesis of Accelerated Hepatitis C Virus Liver Disease Progression
Raymond Chung
Massachusetts Gen Hosp, Boston, US
Liver Transplant in HIV+ Persons: Current Prospects and Prospects for the New Therapeutic Era
Norah Terrault
Univ of California, San Francisco, US
Cure without Interferon: The Scientific Basis and Clinical Evidence
David Thomas
Johns Hopkins Univ, Baltimore, MD, US
from 20th Conference on Retroviruses on March 4, 2013 4:00 PM-6:00 PM
Plenary
The Global MSM HIV Epidemic: Time to Act
Chris Beyrer
Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US
from 20th Conference on Retroviruses on March 5, 2013 8:30 AM-9:00 AM
Plenary
Evolution of the Host–Virus Interaction: A Guide to the Development of Novel Therapeutics?
Jonathan Stoye
MRC-Natl Inst for Med Res, London, UK
from 20th Conference on Retroviruses on March 5, 2013 9:00 AM-9:30 AM
Oral Abstract: HIV/SIV–Host Interaction
Immunologic Profile Distinguishes Aviremic HIV+ Adults
Christina Ramirez Kitchen
Univ of California, Los Angeles, US
Persistent Abnormalities of Lymphoid Structures in HIV Viremic Controllers
Joyce Sanchez
Univ of Minnesota, Minneapolis, US
Prospective ART of Asymptomatic HIV+ Controllers
Hiroyu Hatano
Univ of California, San Francisco, US
Effects of Interferon-α Treatment on Anti-HIV-1 Intrinsic Immunity in vivo
Satish Pillai
Univ of California, San Francisco, US and VAMC, San Francisco, CA, US
Blockade of Type I Interferon during Acute SIV Infection Results in Accelerated Progression to AIDS and Death
Netanya Sandler
NIH, Bethesda, MD, US
Experimental CD4 Depletion in SIV+ Macaques Results in Macrophage and Microglia Infection, Rapid Turnover of Infected Cells, and Encephalitis
Mirko Paiardini
Yerkes Natl Primate Res Ctr, Emory Univ, Atlanta, GA, US
In Vivo Evaluation of a Novel Variant of SIVmac Lacking CD4 Tropism
Adrienne Swanstrom
Univ of Pennsylvania, Philadelphia, US
Neutralization-sensitive Env with Exposed Co-receptor Binding Sites Dominate in vivo during SIV Infection of Macaques Depleted of CD4+ T Cells
Nicholas Francella
Univ of Pennsylvania Perelman Sch of Med, Philadelphia, US
from 20th Conference on Retroviruses on March 5, 2013 10:00 AM-12:00 PM
<< first | < prev page: of 16 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 13 14 15 16 sessions: 1 to 25 of 395